New coronavirus infection (COVID-19) in children with acute lymphoblastic leukemia
D. I. Sadykova,
V. A. Anokhin,
A. I. Ziatdinov,
S. A. Senek,
T. P. Makarova,
N. V. Samoilova,
Ahmed Arafat,
Yu. S. Melnikova https://doi.org/10.21508/1027-4065-2020-65-5-198-203
Abstract
Currently, the researchers from various countries have demonstrated that COVID-19 in children is diagnosed less frequently, and the course and severity of the pathological process is less pronounced than in adults. Children with COVID-19 often have asymptomatic and mild forms. However, the risk of developing severe course of COVID-19 is typical for children from risk groups. Newborns and young children, congenital malformations and concomitant diseases, primarily accompanied by immunodeficiency states of various etiologies (oncological and autoimmune diseases, diabetes mellitus) are the risk factors for the development of severe forms of coronavirus infection. The article presents two clinical cases of COVID-19 in children with acute lymphoblastic leukemia. It is shown that children with concomitant oncohematological pathology often have both mild and severe forms of coronavirus infection.
About the Authors
D. I. Sadykova
Kazan State Medical University
Russian Federation
Russian Federation
V. A. Anokhin
Kazan State Medical University
Russian Federation
Russian Federation
A. I. Ziatdinov
Children's Republican Clinical Hospital
Russian Federation
Russian Federation
Kazan
S. A. Senek
Children's Republican Clinical Hospital
Russian Federation
Russian Federation
Kazan
T. P. Makarova
Kazan State Medical University
Russian Federation
Russian Federation
N. V. Samoilova
Kazan State Medical University
Russian Federation
Russian Federation
Ahmed Arafat
Kazan State Medical University
Russian Federation
Russian Federation
Yu. S. Melnikova
Kazan State Medical University
Russian Federation
Russian Federation
References
1. Namazova-Baranova L.S., Murashkin N.N., Ivanov R.A. Biological therapy in the era of COVID-19. Vprosy sovremennoi pediatrii 2020; 19(2): 116—122. (in Russ.)
2. Zaplatnikov A.L., Svincickaya V.I. COVID-19 and children. RMZH 2020; 28(6): 20-22. (in Russ.)
3. Namazova-Baranova L.S. Coronavirus infection (COVID-19) in children (as of April 2020). Pediatricheskaya farmakologiya 2020; 17 (2): 85-94. (in Russ.). DOI: 10.15690/pf.v17i2.2094
4. Guidelines. Features of the clinical manifestations and treatment of the disease caused by the new coronavirus infection (COVID-19) in children. Version 2 (03.07.2020). (in Russ.).
5. Balduzzi A., Brivio E., Rovelli A., Rizzari C., Gasperini S., Melzi M. et al. Lessons after the early management of the COVID-19 outbreak in a paediatric transplant and haema-to-oncology centre embedded within a COVID-19 dedicated hospital in Lombardia, Italy. Bone Marrow Transplant 2020; 1-6. DOI: 10.1038/s41409-020-0895-4
6. Dong Y., Mo X., Hu Y., Qi X., Jiang F, Jiang Z., Tong S. Epidemiology of COVID-19 Among Children in China. Pediatrics 2020; 145(6): e20200702. DOI: 10.1542/peds.2020-0702
7. Lowensteyn Y.N., Phijfer E.W., Simons J.V.L., Schelte-ma N.M., Mazur N.I., Nair H. et al. Respiratory syncytial virus-related death in children with Down syndrome: the RSV GOLD study. Pediatr Infect Dis J 2020; 39(8): 665-670. DOI: 10.1097/INF.0000000000002666
8. Perez-Padilla R., Fernandez R., Garcia-Sancho C., Franco-Marina F., Aburto O., Lopez-Gatell H. et al. Pandemic (H1N1) 2009 virus and Down syndrome patients. Emerg Infect Dis 2010; 16(8): 1312-1314. DOI: 10.3201/eid1608.091931
9. Zhang C., Wu Z., Li J.W., Zhao H., Wang G.Q. The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality. Int J Antimicrob Agents 2020; 29: 105954. DOI: 10.1016/j.ijantimicag.2020.105954
10. Chen Z, Xiong H., Li J.X., Li H., Tao F., Yang Y.T. et al. COVID-19 with post-chemotherapy agranulocytosis in childhood acute leukemia: a case report. Zhonghua Xue Ye Xue Za Zhi 2020; 41(4): 341-343. DOI: 10.3760/cma.j.issn.0253-2727.2020.0004
11. Feng K., Yun Y.X., Wang X.F., Yang G.D., Zheng Y.J., Lin C.M. et al. Analysis of CT features of 15 children with 2019 novel coronavirus infection. Zhong-hua Er Ke Za Zhi 2020; 58(4):275-278. DOI: 10.3760/cma.j.cn112140-20200210-00071
12. Park J.Y., Han M.S., Park K.U., Kim J.Y., Choi E.H. First Pediatric Case of Coronavirus Disease 2019 in Korea. J Korean Med Sci 2020; 35(11): e124. DOI: 10.3346/jkms.2020.35.e124
13. Alattar R., Ibrahim T.B.H., Shaar S.H., Abdalla S., Shukri K., Daghfal J.N et al. Tocilizumab for the treatment of severe coronavirus disease 2019. J Med Virol 2020; 10.1002/jmv.25964. DOI: 10.1002/jmv.25964
14. Capra R., De Rossi N., Mattioli F., Romanelli G., Scarpazza C., Sormani M. et al. Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia. Eur J Intern Med 2020; 76: 31-35. DOI: 10.1016/j.ejim.2020.05.009
15. Toniati P., Piva S., Cattalini M., Garrafa E., Regola F., Castel-li F. et al. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy. Autoimmun Rev 2020; 19(7): 102568. DOI: 10.1016/j.autrev.2020.102568
Review
For citations:
Sadykova D.I., Anokhin V.A., Ziatdinov A.I., Senek S.A., Makarova T.P., Samoilova N.V., Arafat A., Melnikova Yu.S. New coronavirus infection (COVID-19) in children with acute lymphoblastic leukemia. Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics). 2020;65(5):198-203. (In Russ.) https://doi.org/10.21508/1027-4065-2020-65-5-198-203
Views:
1768
Email this article 